IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 16.950
Totale 16.950
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 16.950
Totale 16.950
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Rapallo 2.505
Genoa 1.768
Bordighera 95
Totale 16.950
Salva come PNG Salva come JPEG
Nome #
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 166
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 149
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 145
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 139
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 128
Targeting bone metastatic cancer: Role of the mTOR pathway 128
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 125
Predicting mood disorders in breast cancer patients. 121
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 120
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 120
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 118
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 117
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 116
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 116
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 116
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 114
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 114
Management of young women with early breast cancer 113
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 112
Fertility, sexuality and cancer in young adult women 112
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 111
Anthracycline-free therapy for HER2-amplified breast cancer 111
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 110
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 110
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 110
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 110
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 110
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 109
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 109
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 108
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 108
News on the medical treatment of young women with early-stage HER2-negative breast cancer 106
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 105
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 105
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 105
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 105
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 104
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 104
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 104
Reply to the letter "Safety of fertility preservation in women with breast cancer" 104
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 104
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 103
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 102
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 101
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 101
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project 101
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 100
Treatment with aromatase inhibitors and markers of cardiovascular disease 100
Randomized cooperative study of perioperative chemotherapy in breast cancer. 99
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 99
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 99
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 98
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 98
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 98
Taxane-containing chemotherapy in the treatment of early breast cancer patients 97
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 97
Letrozole withdrawal response in locally advanced breast cancer 97
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 97
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer 96
Safety of adjuvant aromatase inhibitor therapy 96
Cancer and fertility preservation: international recommendations from an expert meeting 95
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 94
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 93
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 93
A case where switching end points for clinical trial interpretation might be the right choice 93
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors 93
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 93
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 92
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer) 91
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 91
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 90
Long-term follow-up of The Intergroup Exemestane Study 90
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 90
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going 90
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 90
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 89
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 89
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 89
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications 88
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 88
Pharmacokinetics of trastuzumab in haemodialysis 87
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 86
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 86
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 85
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer 85
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 85
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer 85
Role of dose-dense chemotherapy in high-risk early breast cancer 85
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 85
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy. 84
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer 84
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 83
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 82
Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer 82
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. 81
Follow-up of patients with early breast cancer: Is it time to rewrite the story? 81
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group 81
Fertility preservation strategies for breast cancer patients 81
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 81
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 81
Totale 10.111
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.316
article - articoli 61.235
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 81
Totale 122.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019961 0 0 0 0 0 0 0 0 0 0 497 464
2019/20206.315 222 134 146 403 589 836 1.128 578 645 885 584 165
2020/20212.223 156 222 222 224 117 195 136 234 111 287 143 176
2021/20222.704 142 108 128 261 73 302 97 616 279 247 96 355
2022/20233.082 274 249 31 283 448 457 79 379 507 27 308 40
2023/20241.432 72 229 61 256 145 193 128 154 80 110 4 0
Totale 17.824